NeOnc Reports Encouraging Survival Data in Recurrent Brain Cancer Study
Event summary
- NeOnc's Phase 2a study of NEO100 in recurrent brain cancer showed median overall survival of 26.09 months.
- NEO100 is administered intranasally, bypassing the blood-brain barrier with low-grade adverse events reported.
- FDA End-of-Phase 1 meeting for NEO212 program scheduled for November 17, 2026.
- Study involved 24 patients with recurrent or progressive Grade III and Grade IV IDH1-mutant glioma.
The big picture
NeOnc's data adds to a series of 2026 breakthroughs in cancer treatment, highlighting different approaches to challenging diseases. The company's intranasal delivery method and survival data in recurrent brain cancer position it in a niche with urgent unmet needs. The upcoming FDA meeting for NEO212 could further shape its strategic trajectory in the oncology space.
What we're watching
- Regulatory Pathway
- Whether NeOnc can secure a clear registrational development pathway with the FDA for NEO100.
- Clinical Validation
- How subsequent studies will validate the survival signal observed in the Phase 2a trial.
- Competitive Positioning
- The pace at which NeOnc can differentiate itself in the recurrent brain cancer treatment landscape.
Related topics